A number of other brokerages also recently weighed in on DXCM. Zacks Investment Research downgraded DexCom from a buy rating to a hold rating and set a $163.00 price target on the stock. in a report on Monday, August 12th. BMO Capital Markets increased their price objective on DexCom from $180.00 to $190.00 and gave the stock an outperform rating in a research note on Tuesday, September 3rd. UBS Group raised their price objective on DexCom from $140.00 to $160.00 and gave the stock a neutral rating in a research report on Thursday, August 1st. Robert W. Baird lifted their target price on DexCom from $186.00 to $195.00 and gave the company an outperform rating in a research note on Thursday, August 29th. Finally, Raymond James upped their target price on DexCom from $150.00 to $172.00 and gave the company an outperform rating in a report on Thursday, August 1st. Six analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $168.44.
Shares of NASDAQ:DXCM opened at $145.24 on Friday. The firm has a 50 day simple moving average of $160.12 and a 200 day simple moving average of $139.27. DexCom has a 52 week low of $105.05 and a 52 week high of $178.45. The company has a debt-to-equity ratio of 1.56, a quick ratio of 5.64 and a current ratio of 6.05. The company has a market cap of $13.24 billion, a PE ratio of 484.13 and a beta of 0.72.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.07. The firm had revenue of $336.40 million for the quarter, compared to analysts’ expectations of $304.40 million. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The company’s quarterly revenue was up 38.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.10) EPS. On average, equities analysts predict that DexCom will post 0.94 earnings per share for the current year.
In other DexCom news, EVP Jacob Steven Leach sold 5,099 shares of the stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $145.32, for a total transaction of $740,986.68. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Heather S. Ace sold 7,243 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $174.80, for a total value of $1,266,076.40. The disclosure for this sale can be found here. In the last three months, insiders sold 49,235 shares of company stock valued at $7,838,126. 0.88% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in DexCom by 17.2% in the 4th quarter. Geode Capital Management LLC now owns 1,042,131 shares of the medical device company’s stock worth $124,776,000 after purchasing an additional 152,781 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of DexCom by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 164,763 shares of the medical device company’s stock worth $19,738,000 after buying an additional 3,468 shares during the last quarter. Strs Ohio lifted its stake in shares of DexCom by 59.0% in the first quarter. Strs Ohio now owns 2,304 shares of the medical device company’s stock worth $274,000 after buying an additional 855 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of DexCom by 2.8% during the 1st quarter. Arizona State Retirement System now owns 8,084 shares of the medical device company’s stock worth $963,000 after buying an additional 219 shares during the period. Finally, Dupont Capital Management Corp bought a new stake in shares of DexCom during the 1st quarter worth $453,000. 96.79% of the stock is owned by institutional investors.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Read More: Price Target
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.